systemic mycoses
Infectious disease · 2014–2015
2decisions
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| itraconazole Systemic mycoses including systemic aspergillosis, systemic sporotrichosis, systemic histoplasmosis, disseminated pulmonary histoplasmosis infection, chronic… | Nov 2015 | Recommended with restriction | input received |
| itraconazole Treatment of systemic mycoses, including candidiasis, aspergillosis, and histoplasmosis. | Nov 2014 | Not recommended | none received |
What the PBS pays
$1M in government benefit over 2024–25, across 11,509 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| itraconazole | $1.4M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.